Abbott Labs to spend $19.3 billion to buy St. Jude Medical

Abbott Laboratories will spend $19.3 billion to buy St. Jude Medical Inc. in a cash-stock deal that aims to strengthen the medical device maker's stake in cardiovascular care.

Shares of North Chicago-based Abbott plunged, while St. Jude soared today morning after the companies announced the deal.

The combined company will offer devices in nearly every area of cardiovascular care, competing directly with industry leaders Medtronic Inc. and Boston Scientific Corp. It noted that the acquisition will blend St. Jude's pacemaker and implantable defibrillator business with Abbott's focus on artery-opening stents and heart repair products.

Wells Fargo analyst Larry Biegelsen said the deal makes sense because "there is very little overlap" between the companies' offerings. The combined business will be better able to compete with larger companies in the device space, including Johnson & Johnson.

Abbott said St. Jude shareholders will receive $46.75 in cash and a portion of Abbott stock for each St. Jude share. The total consideration adds up to about $85 per share.

That represents a 37 percent premium to Wednesday's $61.95 closing price of St. Jude shares.

The deal value totals $25 billion based on Abbott's recent stock price and assuming about $5.7 million in St. Jude debt.